Healthspan vs lifespan vs longevity and what longevity medicine actually does about the gap

TL;DR

Lifespan is how long you live, healthspan is how many of those years are spent in good health, and longevity medicine is the clinical discipline trying to close the gap between the two.

• The United States has the largest healthspan-lifespan gap of any country tracked by the WHO at 12.4 years (Garmany and Terzic, Nature Communications Medicine 2025).
• Healthspan can be measured today through epigenetic clocks, composite blood-based indices, and functional tests, not only self-report.
• Five interventions have the strongest evidence for extending healthspan: Exercise, sleep, nutrition, social connection, and tobacco avoidance. Most supplements do not.
• Longevity medicine is what happens when those five interventions are personalized, measured, and continuously adjusted, rather than generically prescribed.

Understanding the Vital Gap Between Lifespan and Healthspan

The average American will live around 79 years. Of those, roughly 12 will be spent in a state of disease serious enough to limit daily function. That is the largest healthspan-lifespan gap of any country the World Health Organization tracks. The number does not appear on any longevity marketing site. It appears in the September 2025 issue of Nature Communications Medicine.

The gap is the entire point of the conversation around healthspan vs lifespan vs longevity. Understanding the difference between the three terms is the first step toward understanding why most of modern medicine has been optimizing for the wrong outcome.

What lifespan, healthspan, and longevity actually mean

Lifespan is the simplest of the three. It is the number of years between birth and death. US life expectancy at birth is roughly 79 years per CDC data, lower than most peer high-income countries.

Healthspan is the number of those years lived in good health, free from disabling chronic disease. The WHO measures this at the population level through Healthy Adjusted Life Expectancy, or HALE. Global HALE at birth was 63.5 years per WHO 2019 estimates. The difference between life expectancy and HALE in any country is the healthspan-lifespan gap.

Longevity carries two meanings. In aging research, longevity often refers to exceptional lifespan, including the centenarians and Blue Zone populations. In clinical practice, “longevity medicine” has come to mean something different. It is the discipline aimed at extending healthspan for everyone, not at producing more centenarians.

In a longevity clinic, the word “longevity” is shorthand for the practice itself. The workflow of measuring biomarkers, intervening, and adjusting protocols across years. Both uses of the word are valid. They describe different things.

The structural observation worth keeping is this. The gap between life expectancy and HALE exists in all 183 WHO-tracked countries. No country has closed it.

Why the difference matters

The US gap is 12.4 years out of 79. That is 15.8 percent of average lifespan spent functionally compromised, per the 2025 Garmany and Terzic analysis.

In daily reality, this means most members of a longevity program will not die of old age. They will die of conditions that have been quietly shortening their healthspan for years. Cardiovascular disease, type 2 diabetes, dementia, and the major cancers account for the majority of disability-adjusted life-years lost in middle and older adulthood.

“Longevity isn’t about age anymore. It’s about avoiding chronic disease. Most of us won’t die of ‘old age.’ We’ll die from chronic conditions like diabetes, hypertension, cancer that quietly shorten our healthspan.”

—Samir Mitra, Founder and CEO of Reya.ai.

The public health trajectory is not improving. The 2025 Nature Communications Medicine paper projects the global healthspan-lifespan gap to widen, not close.

The family-level implication is different but equally concrete. The difference between dying at 87 having played with grandchildren the week before and dying at 87 having been bedridden for 14 years is enormous.

The clinical interventions that affect this outcome are decided decades earlier, in a member’s 30s, 40s, and 50s. Across the longevity clinics Reya works with, the patterns predicting those late-life outcomes are visible in lab work that primary care would consider unremarkable.

How healthspan is actually measured

At the population level, HALE does the job. At the individual level, four measurement approaches matter.

1. Biological age estimation through epigenetic clocks: Steve Horvath’s 2013 Genome Biology paper introduced the first clinically usable clock. Newer generations have improved on it. GrimAge (Lu et al. 2019) currently has the strongest correlation with mortality risk of the commercial options. DunedinPACE measures pace-of-aging in years-per-chronological-year, which makes it useful for tracking intervention response rather than just baseline status.
2. Composite aging indices calculated from standard labs: PhenoAge uses nine routine blood markers to estimate biological age. For most clinics, it is the cheapest credible option. Frailty indices serve a similar purpose in older populations.
3. Functional testing: VO2 max, grip strength, gait speed, and the six-minute walk test each predict mortality and disability independent of chronological age. These tests are cheap, repeatable, and meaningful.
4. Body composition: A DEXA scan reports lean mass, bone density, and visceral adipose tissue. Tracking those over years is more clinically useful than tracking weight or BMI.

One important caveat is that no single number captures healthspan. The clinical signal is in tracking change over time across multiple modalities. And the modalities themselves are moving targets. Three of the four major epigenetic clock vendors release annual algorithm updates, which means longitudinal tracking is effectively vendor-lock-in tracking. Few people in the field discuss this openly.

Compression of morbidity, the real goal of longevity medicine

The concept that actually organizes serious longevity medicine is older than most members of the field. James Fries proposed it in the New England Journal of Medicine in 1980. He called it compression of morbidity.

The idea is to push the period of disease and disability as close to the end of life as possible. The goal is not to live longer in a hospital bed. The goal is to live healthy until you die, with a short final decline rather than a multi-decade one.

A 2025 Nature Communications paper by Karin and colleagues formalized the alternative scenarios.

Lifespan extension can come in three shapes.

1. Morbidity expansion, where extra years are mostly years of disease.
2. Proportional stretching, where the healthy and unhealthy periods both grow.
3. True compression, where healthspan grows faster than lifespan.

Empirically, the global trajectory is closer to expansion than compression. The 2025 Garmany and Terzic data shows the gap widening, not closing.

The implication for clinical practice is straightforward. Extending lifespan without compressing morbidity is a failure mode of medicine. Longevity medicine, done seriously, is explicitly aimed at compression. That is the standard the field should be judged against.

What actually extends healthspan

The evidence-graded list has not changed much in fifteen years.

Five interventions dominate the peer-reviewed literature.

1. Movement: Current guidance from the AHA and WHO converges on 150 to 300 minutes per week of moderate-intensity activity, or 75 to 150 minutes of vigorous activity, plus resistance training two to three times per week. UK Biobank step-count analyses show that most of the mortality benefit is captured by roughly 7,000 to 8,000 steps per day.
2. Sleep: Seven to nine hours of quality sleep per night. Adherence is the issue. Across the longevity clinics Reya works with, sleep is the single most under-addressed pillar at intake. Members frequently arrive optimizing supplements while sleeping 5.5 hours.
3. Nutrition: Mediterranean and MIND-style eating patterns have the most consistent population-level signal. Calorie quality matters more than calorie counting at the population level. Disordered-eating considerations apply at the individual level and should not be ignored.
4. Social connection: The US Surgeon General’s 2023 advisory framed loneliness as a public health concern with mortality risk comparable to smoking 15 cigarettes a day.
5. Tobacco avoidance: Tobacco accounts for roughly 8 million deaths globally per year per WHO data. Excess alcohol consumption is the close-related cousin.

“Adding a year to your life doesn’t require a lifestyle overhaul. It just requires: 5 minutes more sleep. 2 minutes more movement. Half a serving of vegetables. But reach optimal levels, and the gains compound: 7-8 hours of nightly sleep, 42+ minutes of daily activity, consistently high-quality nutrition. That’s associated with 9+ additional disease-free years.”

—Samir Mitra, Founder and CEO of Reya.ai. LinkedIn

What is overhyped or unproven

Most supplements marketed as longevity boosters have weak human evidence. The gap between mouse data and human RCT data is well documented and rarely acknowledged in consumer marketing. Resveratrol, NMN, and most other “longevity” supplements have small or null effects in the human trials that exist.

Caloric restriction and intermittent fasting show real signal in model organisms. In humans, the evidence is mixed to modest, with adherence challenges and disordered-eating concerns making them harder to recommend universally.

Biological age reversal marketing outpaces science. Real biomarker movement does occur with sustained lifestyle change. The “10 years younger in 8 weeks” claims that show up in consumer advertising are not what the underlying studies actually demonstrate.

The “10,000 steps” benchmark has a similar problem. It originated in 1960s Japanese marketing for a pedometer brand. The current evidence threshold is closer to 7,000.

“Science often refines what culture turns into a slogan. ‘10,000 steps’ was marketing; ‘7,000 steps’ may well be medicine.”

—Samir Mitra, Founder and CEO of Reya.ai. LinkedIn post 24, August 2025.

What longevity medicine adds

Longevity medicine is the clinical application of the P4 framework (predictive, preventive, personalized, participatory) to healthspan extension. The five-pillar lifestyle list is the foundation. Longevity medicine is what happens when that foundation is operationalized.

There are four additions:

• Continuous measurement, where biomarkers, wearables, and biological age tests replace annual snapshots.
• Personalized intervention, where protocols are tuned to the individual’s genetic, metabolic, and lifestyle profile rather than to population averages.
• Longitudinal adjustment, where the plan is updated based on trajectory rather than re-prescribed once a year.
• And behavior-change architecture, which is the part hardest to operationalize and easiest to underestimate.

The difference from concierge primary care is real. A good concierge practice is built around faster access and more attention. A longevity practice is built around continuous data and structured protocol adjustment over years.

Different problems, different software, different workflow.

“The key issue in longevity medicine is that you must get people to change their behavior, and so you need a system that is going to basically enable behavior change. That’s what we built Reya.ai to do.”

—Samir Mitra, Founder and CEO of Reya.ai. Longevity.Technology interview, February 2025.

Three takeaways earn their place

1. Lifespan is finite, healthspan is largely earned, and longevity medicine is the discipline that tries to align the two.
2. The boring lifestyle work is most of the gain. Exercise, sleep, nutrition, social connection, and avoiding tobacco account for the majority of the achievable extension.
3. The measurement and personalization layer closes the rest of the gap, and it requires real infrastructure to deliver consistently.

Reya was built around the assumption that the boring stuff has to be tracked, personalized, and continuously adjusted, not prescribed once and forgotten.

Frequently Asked Questions

References

1. Garmany, A. & Terzic, A. (2025). Healthspan-lifespan gap differs in magnitude and disease contribution across world regions. Communications Medicine 5. https://doi.org/10.1038/s43856-025-01111-2 
2. Cooper, R., Kuh, D. & Hardy, R. (2010). Objectively measured physical capability levels and mortality: systematic review and meta-analysis. BMJ 341. https://doi.org/10.1136/bmj.c4467 
3. Cruz, B. D., Ahmadi, M., Sabag, A., Maurice, P. F., Lee, I. & Stamatakis, E. (2025). Step Accumulation Patterns and Risk for Cardiovascular Events and Mortality Among Suboptimally Active Adults. Annals of Internal Medicine. https://doi.org/10.7326/annals-25-01547 
4. Wise, J. (March 8, 2024). Sixty seconds on . . . 10 000 steps. BMJ 2024; 384. https://www.bmj.com/content/384/bmj.q598 
5. Yang, Y., Mayo, A., Levy, T., Raz, N., Shenhar, B., Jarosz, D. F. & Alon, U. (2025). Compression of morbidity by interventions that steepen the survival curve. Nature Communications 16. https://doi.org/10.1038/s41467-025-57807-5 
6. Fries, J. F. (1980). Aging, Natural Death, and the Compression of Morbidity. New England Journal of Medicine 303(3), pp. 130-135. https://doi.org/10.1056/NEJM198007173030304 
7. McGrath, R., Snih, S. A., Markides, K., Hall, O. & Peterson, M. (2019). The burden of health conditions for middle-aged and older adults in the United States: disability-adjusted life years. BMC Geriatrics 19(1). https://doi.org/10.1186/s12877-019-1110-6 
8. (2021). Life expectancy and Healthy life expectancy. World Health Organization. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-life-expectancy-and-healthy-life-expectancy 
9. Skiadas, C. H. (2011). Life Expectancy at Birth, Estimates and Forecasts in the Netherlands (Females). arXiv preprint. https://doi.org/10.48550/arXiv.1112.0796